2-(dimethylamino)ethyl (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate | 147565-72-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-(dimethylamino)ethyl (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate
• CAS: 147565-72-8
• 化学式: C₂₄H₃₉NO₂
• 分子量: 373.579
• InChiKey: QBFZJHZAMSYEIV-AAQCHOMXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  27
• 可旋转键数：
  17
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(dimethylamino)ethyl (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate 、 碘甲烷 以 甲醇 为溶剂， 反应 0.08h， 生成
  参考文献：
  名称：

  Improved LC−MS Method for the Determination of Fatty Acids in Red Blood Cells by LC−Orbitrap MS

  摘要：

  我们报告了一种通过液相色谱质谱联用（LC−MS）快速且灵敏分析红细胞（RBC）中生物学相关的脂肪酸（FAs）的新方法。该方法开发了一种形成吡啶甲酰胺的新化学衍生化途径，通过定量反应从FAs中生成。包括从C14到C22的饱和及不饱和FAs在内的14种衍生化FA标准品，在15分钟内得以高效分离。此外，采用最近推出的台式轨道阱质谱仪在正离子电喷雾电离（ESI）全扫描模式下进行检测，相较于传统串联MS方法，灵敏度提高了2至10倍，对饱和及不饱和FAs的检测限达到了低飞摩尔水平。所开发的方法被应用于测定RBC中的FA浓度，其日内和日间变异系数均低于10%。

  DOI：

  10.1021/ac103093w
• 作为产物：
  描述：

  全顺式二十碳五烯酸 在 草酰氯 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 0.16h， 生成 2-(dimethylamino)ethyl (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate
  参考文献：
  名称：

  Improved LC−MS Method for the Determination of Fatty Acids in Red Blood Cells by LC−Orbitrap MS

  摘要：

  我们报告了一种通过液相色谱质谱联用（LC−MS）快速且灵敏分析红细胞（RBC）中生物学相关的脂肪酸（FAs）的新方法。该方法开发了一种形成吡啶甲酰胺的新化学衍生化途径，通过定量反应从FAs中生成。包括从C14到C22的饱和及不饱和FAs在内的14种衍生化FA标准品，在15分钟内得以高效分离。此外，采用最近推出的台式轨道阱质谱仪在正离子电喷雾电离（ESI）全扫描模式下进行检测，相较于传统串联MS方法，灵敏度提高了2至10倍，对饱和及不饱和FAs的检测限达到了低飞摩尔水平。所开发的方法被应用于测定RBC中的FA浓度，其日内和日间变异系数均低于10%。

  DOI：

  10.1021/ac103093w

文献信息

• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF RENAL DISEASES<br/>[FR] COMPOSITIONS ET MÉTHODES POUR LE TRAITEMENT DE NÉPHROPATHIES
  申请人：MOHAN M ALAPATI

  公开号：WO2016046670A1

  公开（公告）日：2016-03-31

  The compositions and compounds of formula I which includes a salt of pyridoxamine or its polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, nanoparticle, buccal administration or transdermal administration. Such compositions may be used to treatment of kidney disease, diabetic renal diseases, chronic kidney disease, albuminuria, or its associated complications.

  公式I的组合物和化合物包括吡啶醇盐或其多晶形、对映体、立体异构体、溶剂合物和水合物。这些盐可以制成药物组合物。药物组合物可以制成口服、延迟释放或持续释放、经粘膜、糖浆、局部、肠道、注射、皮下、口服溶液、直肠给药、纳米颗粒、颊黏膜给药或经皮给药的制剂。这些组合物可用于治疗肾脏疾病、糖尿病肾病、慢性肾脏疾病、白蛋白尿或其相关并发症。
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES AND PRE-DIABETES
  申请人：Alapati Mohan Murali

  公开号：US20170073345A1

  公开（公告）日：2017-03-16

  The invention relates to the compounds and compositions of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprises a salt of dipeptidyl peptidase-4 inhibitor and the methods for treating or preventing metabolic syndrome, prediabetes and diabetes may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compounds and compositions may be used to treatment of diabetes mellitus, obesity, lipid disorders, hypertriglyceridemia, hyperglycemia, hyperinsulinemia and insulin resistance.
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEPRESSION AND NEUROLOGICAL DISEASES<br/>[FR] COMPOSITIONS ET MÉTHODES DE TRAITEMENT DE LA DÉPRESSION ET DE MALADIES NEUROLOGIQUES
  申请人：MOHAN M ALAPATI

  公开号：WO2016046669A2

  公开（公告）日：2016-03-31

  The invention relates to the compounds and compositions of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II, and methods for treating or preventing depression and neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of major depression, obsessive-compulsive disorder (OCD), body dysmorphic disorder (BDD), posttraumatic stress disorder (PTSD), premenstrual dysphoric disorder (PMDD), panic disorder and social phobia (social anxiety disorder), premature ejaculation and vascular headaches.
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND DIABETES<br/>[FR] COMPOSITIONS ET MÉTHODES UTILISABLES À DES FINS DE TRAITEMENT DES MALADIES CARDIOVASCULAIRES ET DU DIABÈTE
  申请人：MOHAN M ALAPATI

  公开号：WO2016046672A1

  公开（公告）日：2016-03-31

  The compositions and compounds of formula I which includes a salt of ranolazine or its polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of angina, angina pectoris, diabetes, hyperglycemia, elevated glucose levels, deep venous thrombosis, prevention of secondary venous thromboembolism and complications of atrial fibrillation such as stroke and additional risk factor for stroke.
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER METABOLIC DISEASES<br/>[FR] COMPOSITIONS ET PROCÉDÉS DE TRAITEMENT DE MALADIES MÉTABOLIQUES HÉPATIQUES
  申请人：MOHAN M ALAPATI

  公开号：WO2016046680A2

  公开（公告）日：2016-03-31

  The invention relates to the compositions of formula I, formula II, formula III, formula IV, formula V and formula VI or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprises a salt of bile acid and the methods for treating or preventing liver diseases, fatty liver, NASH, metabolic syndrome, prediabetes and diabetes may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of NASH, Fatty liver, liver cirrhosis and metabolic syndrome.